News

Ascletis’ NASH Drug ASC41(THRβ) Phase II Enrollment is Progressing as Planned
21/12/2022
Ascletis Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022
07/11/2022
SAGIMET BIOSCIENCES ANNOUNCES POSITIVE INTERIM PHASE 2B CLINICAL TRIAL DATA WITH DENIFANSTAT (TVB-2640), A FIRST-IN-CLASS FATTY ACID SYNTHASE INHIBITOR, IN MODERATE-TO-SEVERE NON-ALCOHOLIC STEATOHEPATITIS (NASH) PATIENTS
04/11/2022
Ascletis Announces Dosing of the First Patient in Phase II Clinical Trial of THRβ Agonist ASC41 for 52-Week Treatment of Liver Biopsy-Proven NASH
05/10/2022
Gannex Announces First Subject Dosed in the U.S. Drug-Drug Interaction Study of FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis
16/08/2022
Gannex Announces U.S. FDA Clearance of Clinical Trial on FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis
08/06/2022
Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis
10/04/2022
Gannex Announces Completion of the U.S. Phase I Trial of ASC43F, an In-House Developed First-in-Class Dual Targeting Fixed-dose Combination Tablet for NASH
04/01/2022